Identifies a novel POMT1 mutation associated with a milder phenotype of congenital muscular dystrophy, expanding the known clinical spectrum.
Answers are grounded in this paper and cite their sources.
May broaden genetic testing in atypical dystrophy cases; extends spectrum but requires validation in larger cohorts.
INTRODUCTION: Congenital muscular dystrophies (CMD) with hypoglycosylated α-dystroglycan due to POMT1 mutations are associated with clinical phenotypes that vary in severity. METHODS: We describe a patient with congenital hypotonia, generalized weakness, elevated creatine kinase (CK), and normal brain imaging. RESULTS: Histochemical analysis of the index case's muscle showed deficiency of glycosylated α-dystroglycan and secondary merosin deficiency. Genetic testing revealed a novel mutation in exon 20 of the POMT1 gene. CONCLUSIONS: Our patient's milder form of CMD adds to the emerging evidence of an expanding phenotype caused by POMT1 mutations. The histopathological findings of the muscle biopsy in this case support the need for careful clinical, genetic, and histochemical diagnostic interpretation.
No takes yet. Share an insight, caveat, or question.
Al-Zaidy et al. (2011) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: